Sensible Biotechnologies raises $47M Series A for cell-made mRNA
Oxford Science Enterprises leads a $47M Series A for Sensible Biotechnologies, whose engineered cells produce naturally modified mRNA, plus up to $20M non-dilutive for Slovak manufacturing.
Also see more funding coverage: /funding/
Founded 2021 · Oxford, United Kingdom
Sensible Biotechnologies, the Oxford-headquartered mRNA company founded by two Slovak biomedical engineers, has raised a $47M Series A led by Oxford Science Enterprises to scale a platform that manufactures mRNA inside living cells rather than in a glass reactor.
The round, announced on 6 October 2026, brings OTB Ventures and In-Q-Tel onto the cap table as new investors, with existing backers Recode Ventures, Isomer Capital, Y Combinator, Backed VC, Kaya VC, Civilization Ventures and BlueYard Capital returning, joined by the family office of BioNTech co-founder Christoph Huber and former Eli Lilly chief medical officer Tim Garnett (company announcement, 6 October 2026). On top of the equity sits up to $20M in non-dilutive funding from EU, NATO-linked and government programmes, pointed squarely at clinical-grade manufacturing in Slovakia.
The use of funds follows the announcement’s own words: development and scale-up of the company’s VECTOR platform, expansion of its AI-enabled mRNA design and automated high-throughput screening, and the build-out of clinical-grade manufacturing capabilities.
Below, I lay out what Sensible actually makes, the manufacturing market it is stepping into, and why a Slovak-founded company closing a $47M biotech Series A is a pattern worth keeping.
A syndicate running from Oxford to Langley
Oxford Science Enterprises leading is the expected part: the university-anchored fund exists to turn Oxford science into companies, and Sensible’s discovery work sits in the city. The eyebrow-raiser is In-Q-Tel, the venture arm of the US intelligence community, writing into an Oxford-Bratislava mRNA platform. That is not vaccine nostalgia; it is a biosecurity position. Whoever controls fast, clean mRNA production controls part of the response to the next pathogen, and strategic investors have noticed.
The rest of the table tells a European story: Kaya VC out of Prague backing founders from its own region, and Christoph Huber, the Mainz oncologist who co-founded BioNTech, putting family office money behind the next generation of the technology he helped take mainstream.
mRNA brewed in cells, not synthesised in tubes
Founded in 2021 by CEO Miroslav Gasparek and chief scientific officer Marian Kupculak, both biomedical engineers, Sensible Biotechnologies went through Y Combinator before building out three sites: discovery in Oxford, process development in Bratislava, and cGMP scale-up in Sarisske Michalany in eastern Slovakia (company website, October 2026).
Conventional mRNA medicines are synthesised chemically, by in-vitro transcription. Sensible engineers living cells to do the production instead, yielding what it calls naturally modified mRNA: reduced immunogenicity, higher protein expression, and no double-stranded RNA contamination, the impurity that synthetic production has to purify away (company announcement, 6 October 2026). PromPT, the company’s programmable mRNA protein transporter, captures and protects the target molecule inside the cell before extraction. A strategic partnership with Sartorius is meant to carry the platform toward clinical-grade manufacturing.
“mRNA transformed vaccines, but we believe its greatest potential lies in therapeutics,” says Gasparek in the announcement. “We are taking a fundamentally different approach, using living cells to produce naturally modified mRNA while reducing the cost and supply-chain constraints of conventional production.”
A $5bn manufacturing market compounding at 10%
The market Sensible sells into is the making of mRNA, not any single drug. The global mRNA therapeutics CDMO market was worth $5.0bn in 2024 and is projected to reach $9.0bn by 2030, a 10.3% CAGR (Research and Markets, August 2025). A platform that promises cleaner mRNA at lower cost is a direct play on that growth, whether Sensible manufactures for partners or licenses the method.
For scale, look at our own fundraising data this fortnight: Breye Therapeutics raised a €67.5M Series A for an oral eye drug and Aptadir closed a €40M seed for RNA-targeting therapeutics. A $47M Series A for a manufacturing platform, rather than a clinical asset, sits comfortably in that band – European investors are now pricing biotech infrastructure like they price pipelines.
Bratislava is on the mRNA map
So what does this round signal? Europe learned during the pandemic that mRNA capacity concentrated in a handful of plants is a strategic liability. The good news is the answer is being built here: Slovak founders who could have stayed in California after Y Combinator are instead putting process development in Bratislava and a cGMP site in eastern Slovakia, with public money from Slovakia and the EU stacked beside the equity.
We talk a lot about Mainz when we talk about European mRNA. Watch the Oxford-Bratislava axis instead: university science at one end, manufacturing in a region that rarely gets deep tech rounds of this size at the other, and American strategic capital crossing the Atlantic to be part of it – not the other way round. If clinical-grade batches come out of Sarisske Michalany in the next two years, Europe’s mRNA story stops being a one-city story. Let’s watch it get built.
